We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Tests Evaluated for Chronic Chagas Disease Patients

By LabMedica International staff writers
Posted on 05 Oct 2021
Print article
Image: Examples of negative and positive Chagas Stat-Pak RDT results. From left to right, negative, weakly positive, and strongly positive Stat-Pak results are shown (Photo courtesy of Yves Jackson)
Image: Examples of negative and positive Chagas Stat-Pak RDT results. From left to right, negative, weakly positive, and strongly positive Stat-Pak results are shown (Photo courtesy of Yves Jackson)
Chagas is a disease caused by the parasite Trypanosoma cruzi, and is one of the most important public health concerns affecting the population of Latin America. This disease presents an acute phase that generally goes undiagnosed and a chronic phase with cardiac manifests principally, is diagnosed through serological tests that are generally not available.

In the Americas, up to 99% of cases of Chagas Disease (CD) and more than 90% of cases of CD in Europe are undiagnosed. Serological diagnosis in the chronic phase of CD is based on the detection of circulating antibodies through conventional reactions such as the enzyme-linked immunosorbent assay (ELISA) test, Indirect Immunofluorescence (IIF), Indirect Hemagglutination (IHA), Chemiluminescence (ChLIA) and Western blot/Immunoblot.

A group of international scientists led by the Universitat Autònoma de Barcelona (Barcelona, Spain) evaluated the diagnostic precision of two rapid diagnostic tests (RDT’s) on patients with chronic CD. They included in the study 305 participants from rural and urban area of Colombia of which 215 were negative for T. cruzi and 90 were positive according to the reference criteria. Of the participants, 60.7% were women, 39.3% were men, the median age was 47.1 ± 18.5years old, the youngest participant was 3 years old and the oldest participant was 80 years old.

All samples were analyzed using the ELISA Chagas III tests (GrupoBios, Santiago, Chile) and with the Chagas ELISA IgG+IgM tests (Vircell, Granada, Spain) as reference standards. The Two RDT’s were performed to all participants were the Chagas Detect Plus (CDP, InBios, Seattle, WA, USA) and the Chagas Stat-Pak (CSP, Chembio Diagnostic, Hauppauge, NY, USA).

The scientists reported that 305 subjects were included in the study (38 patients with leishmaniasis), of which 215 tested negative for T. cruzi and 90 tested positive according to the reference standard. The sensitivity of the RDT’s were 100% (CI 95% 95.9–100), and the specificity of the CDP was 99.1% (CI 95% 96.6–99.8) and for CSP was 100% (CI 95% 98.3–100). The agreement of CDP was 99.5% and for CSP was 100% with Kappa values of (k = 99.1; CI 95% 92.6–99.8%) and (k = 100; CI 95% 94.3–100), respectively. RDT’s did not present cross-reactions with samples from patients who were positive for leishmaniasis.

The authors concluded that the findings demonstrated excellent results from the RDT’s in terms of validity, safety, and reproducibility. The results obtained provide evidence for the recommendation for using these tests in a Colombian epidemiological context principally in endemic areas in which laboratory installations necessary to perform conventional tests are not available, or they are scarce and to help in diagnosing chronic Chagas disease in order to provide access to treatment as soon as possible. The study was published on June 2, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Universitat Autònoma de Barcelona
GrupoBios
Vircell
InBios
Chembio Diagnostic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.